SenzaGen AB (SENZA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SenzaGen AB (SENZA) has a cash flow conversion efficiency ratio of -0.052x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-3.85 Million ≈ $-414.75K USD) by net assets (Skr74.24 Million ≈ $7.99 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
SenzaGen AB - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how SenzaGen AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read SenzaGen AB debt and liabilities for a breakdown of total debt and financial obligations.
SenzaGen AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SenzaGen AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pointerra Ltd
AU:3DP
|
2.015x |
|
Primega Group Holdings Limited Ordinary Shares
NASDAQ:PGHL
|
N/A |
|
Yulho Co. Ltd
KQ:072770
|
-0.042x |
|
Carnavale Resources Limited
F:YBB
|
-0.009x |
|
Ridgeline Minerals Corp
V:RDG
|
0.016x |
|
Samyang Holdings Corp
KO:000075
|
0.036x |
|
Enex Co.Ltd
KO:011090
|
-0.049x |
|
Riverside Resources Inc
V:RRI
|
-0.062x |
Annual Cash Flow Conversion Efficiency for SenzaGen AB (2014–2024)
The table below shows the annual cash flow conversion efficiency of SenzaGen AB from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see SenzaGen AB (SENZA) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr86.64 Million ≈ $9.32 Million |
Skr-9.33 Million ≈ $-1.00 Million |
-0.108x | +55.75% |
| 2023-12-31 | Skr67.61 Million ≈ $7.28 Million |
Skr-16.45 Million ≈ $-1.77 Million |
-0.243x | -35.83% |
| 2022-12-31 | Skr89.70 Million ≈ $9.65 Million |
Skr-16.07 Million ≈ $-1.73 Million |
-0.179x | +5.86% |
| 2021-12-31 | Skr110.24 Million ≈ $11.86 Million |
Skr-20.98 Million ≈ $-2.26 Million |
-0.190x | +30.17% |
| 2020-12-31 | Skr107.79 Million ≈ $11.60 Million |
Skr-29.38 Million ≈ $-3.16 Million |
-0.273x | -17.68% |
| 2019-12-31 | Skr134.21 Million ≈ $14.44 Million |
Skr-31.08 Million ≈ $-3.34 Million |
-0.232x | +14.26% |
| 2018-12-31 | Skr85.94 Million ≈ $9.25 Million |
Skr-23.21 Million ≈ $-2.50 Million |
-0.270x | -134.27% |
| 2017-12-31 | Skr101.01 Million ≈ $10.87 Million |
Skr-11.65 Million ≈ $-1.25 Million |
-0.115x | +61.09% |
| 2016-12-31 | Skr32.71 Million ≈ $3.52 Million |
Skr-9.69 Million ≈ $-1.04 Million |
-0.296x | -96.27% |
| 2015-12-31 | Skr41.61 Million ≈ $4.48 Million |
Skr-6.28 Million ≈ $-675.94K |
-0.151x | -129.67% |
| 2014-12-31 | Skr2.05 Million ≈ $220.61K |
Skr1.04 Million ≈ $112.24K |
0.509x | -- |
About SenzaGen AB
SenzaGen AB provides non-animal tests for assessing allergenicity. The company offers GARD skin OECD 442E, GARD skin dose-response, GARD skin medical device; and GARD air, a respiratory sensitization assessment. It also provides biological evaluation, in vitro biocompatibility testing, cytotoxicity, irritation, and skin sensitization medical device services; advisory services for medical devices;… Read more